In this review, we concentrate on the recent progress [11] in the discovery and characterization of biased agonists acting at the β2-adrenergic receptor (β2AR), a Gs-coupled receptor that is expressed on many cell types and is the target for therapeutically administered agonists for treating obstructive lung disease. Here, ADRB2 is linked to Airway obstruction.